Sandra Poole Net Worth

Sandra Poole biography

Sandra Poole serves as Independent Director of the Company. Ms. Poole served as the Chief Operating Officer of LogicBio Therapeutics, Inc., a genome editing company from April 2018 to March 2019, and of Candel Therapeutics, a biotechnology company, from January 2020 to March 2020. Prior to LogicBio, Ms. Poole held executive roles of increasing responsibility at ImmunoGen, Inc., a company developing antibody-drug conjugates (ADCs) to treat cancer, including serving as Senior Vice President of Technical Operations from September 2014 to July 2015, Executive Vice President, Technical Operations from July 2015 to October 2016 and Executive Vice President, Technical Operations and Commercial Development from October 2016 to January 2017. From February 2017 to March 2018 Ms. Poole served as managing director of S.E.P. Life Sciences Consulting LLL (formerly S. Poole Consulting LLC), a biopharmaceutical consulting company. Before joining ImmunoGen, Ms. Poole spent more than 15 years in global manufacturing and development leadership positions at Genzyme (now Sanofi Genzyme). Ms. Poole currently serves on the supervisory board for Valneva, SE, a France-based vaccine company. She is also a member of the board of directors of ViaCyte, a company focused on regenerative medicine technology to address beta cell loss in type 1 diabetes. Ms. Poole holds an M.A.Sc. and a B.A.Sc. in chemical engineering from the University of Waterloo (Canada).

What is the salary of Sandra Poole?

As the Independent Director of Retrophin, the total compensation of Sandra Poole at Retrophin is 340,225$. There are 7 executives at Retrophin getting paid more, with Eric Dube having the highest compensation of 9,679,320$.

How old is Sandra Poole?

Sandra Poole is 56, she's been the Independent Director of Retrophin since 2019. There are 5 older and 8 younger executives at Retrophin. The oldest executive at Retrophin, Inc. is Gary Lyons, 68, who is the Independent Chairman of the Board.

What's Sandra Poole's mailing address?

Sandra's mailing address filed with the SEC is C/O RETROPHIN, INC., 3721 VALLEY CENTRE DR., STE 200, SAN DIEGO, CA, 92130.

Insiders trading at Retrophin

Over the last 12 years, insiders at Retrophin have traded over 26,547,782$ worth of Retrophin stock and bought 585,006 units worth 5,991,663$ . The most active insiders traders include Martin Shkreli、Ron Squarer、Steve Aselage. On average, Retrophin executives and independent directors trade stock every 23 days with the average trade being worth of 1,651$. The most recent stock trade was executed by Laura Clague on 23 November 2020, trading 7,500 units of RTRX stock currently worth 174,675$.

What does Retrophin do?

Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Retrophin executives and stock owners

Retrophin executives and other stock owners filed with the SEC include:

• Eric Dube,
  President, Chief Executive Officer, Director
• Elizabeth Reed,
  Senior Vice President, General Counsel and Corporate Secretary
• Noah Rosenberg,
  Chief Medical Officer
• Peter Heerma,
  Chief Commercial Officer
• William Rote,
  Senior Vice President and Head of Research and Development
• Laura Clague,
  Chief Financial Officer, Senior Vice President
• Stephen Aselage,
  Director
• Sandra Poole,
  Independent Director
• Gary Lyons,
  Independent Chairman of the Board
• Timothy Coughlin,
  Independent Director
• Jeffrey Meckler,
  Independent Director
• John Orwin,
  Independent Director
• Roy Baynes,
  Independent Director
• Ron Squarer,
  Independent Director
• Suzanne Bruhn,
  Independent Director
• Neil F. Mc Farlane,
  Chief Operating Officer
• Jensen Margaret E Valeur,
  General Counsel
• John W Kozarich,
  Director
• Alvin Shih,
  EVP of Research & Development
• Cornelius E Golding,
  Director
• Steve Aselage,
  Director
• Martin Shkreli,
  Chief Executive Officer
• Steven Gary Richardson,
  Director
• Horacio Plotkin,
  Chief Medical Officer
• Jeffrey Paley,
  Director
• Marc L Panoff,
  Chief Financial Officer